Peripheral T-Cell Lymphoma
Conditions
Keywords
Peripheral T-Cell Lymphoma (PTCL), Relapsed, Refractory, CD30 Receptor, Large B-Cell Lymphoma
Brief summary
The main purpose of this study is to test if brentuximab vedotin has an effect on cancer in patients with a certain type of large B-cell lymphoma. The side effects (unwanted effects) of SGN-35 in patients with this certain type of large B-cell lymphoma will also be studied. It is not known if brentuximab vedotin is better or worse than other treatment patients might be given.
Interventions
DRUGBrentuximab vedotin
Brentuximab vedotin will be given by intravenous infusion (into a vein) on Day 1 of every 21 day cycle.
Sponsors
Seagen Inc.
H. Lee Moffitt Cancer Center and Research Institute
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Confirmed diagnosis of PTCL expressing CD30 receptor. Following PTCL subtypes will be eligible: Peripheral T - cell lymphoma, not otherwise specified (NOS); Angioimmunoblastic T-cell Lymphoma; Subcutaneous Panniculitis Like T-cell Lymphoma; Hepatosplenic gamma/delta T cell Lymphoma; Extranodal natural killer (NK)T-cell Lymphoma, nasal type; Enteropathy-associated T-cell lymphoma; Adult T-cell Leukemia/lymphoma; T-cell prolymphocytic leukemia; Primary cutaneous gamma-delta T-cell lymphoma; Aggressive NK cell leukemia; Aggressive subtype of T cell Large Granular Lymphocytic (LGL) or transformed LGL leukemia; Epstein Barr Virus(EBV)-positive T-cell lymphoproliferative disorders of childhood; Transformed mycosis fungoides who have progressed following treatment with at least one systemic therapy; Sezary syndrome * Histology slides and pathology material must be available at the site for each patient before enrollment in order to be sent to the Leading Institution of the study for central pathology review and pharmacodynamic studies. * Patients must have progressive, relapsed or refractory disease after: At least one prior systemic anti-lymphoma regimen (chemotherapy or immunotherapy except for transformed mycosis fungoides as described previously); Relapsed or failed autologous or allogeneic stem cell transplant. * Understand and voluntarily sign an Institutional Review Board (IRB) approved informed consent form * Must have at least one site of disease (index lesion) measurable in two dimensions by computed tomography (CT) * Patients with leukemic form of PTCL who will not have a measurable lesion in two dimensions by CT scan, relapsed or refractory disease must be detected by immunohistochemistry or flow cytometry and molecular clonality studies in bone marrow or peripheral blood. * At least 2 weeks since the last chemotherapy, radiation therapy, immunotherapy or any investigational products * Must meet the following criteria within 4 days before the first dose of study drug: * Neutrophils ≥1,000/ul * Hemoglobin ≥ 8 g/dL * Platelets≥ 50.0x10\^9 /L * Total bilirubin ≤ 1.5 x upper normal limit, or ≤ 5 x upper normal limit if documented hepatic involvement with lymphoma or history of Gilbert's Syndrome * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x upper normal limit (≤ 5 x upper normal limit if documented hepatic involvement with lymphoma) * Calculated creatinine clearance ≥ 40 mL/min/1.73 m\^2 based on Cockcroft and Gault method * PT or International Normalization Ratio (INR), and Activated Partial Thromboplastin Time (APTT) ≤ 1.5 x upper limit of normal unless patient is receiving anticoagulants. If patient is on anticoagulation therapy, levels should be within therapeutic range. * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Negative pregnancy test for women of childbearing potential * Recovered (≤ Grade 1 toxicity) from the reversible effects of prior antineoplastic therapy
Exclusion criteria
* Any of the following cardiovascular conditions or values within 6 months before the first dose of study drug: Myocardial infarction and the New York Heart Association (NYHA) Class III or IV heart failure * History of another primary malignancy not in clinical remission; except adequately treated patients with completely resected in situ carcinoma, such as nonmelanoma skin cancer and cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on Pap smear, or localized prostate cancer with prostate-specific antigen (PSA) \<1 ng/ml * Known active cerebral/meningeal involvement with lymphoma. Asymptomatic patients with previously treated and resolved central nervous system (CNS) lymphoma involvement are permitted. * Prior administration of Brentuximab vedotin * Corticosteroid monotherapy for lymphoma within 1 week of the first dose of study drug * Any serious underlying medical condition that, in the opinion of the investigator or medical monitor, would impair the ability to receive or tolerate the planned treatment * Known hypersensitivity to recombinant proteins, or any component contained in the drug formulation * Female patients who are lactating or have a positive serum pregnancy test during the screening period
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Response Rate (ORR) | Up to 24 months post treatment | ORR: The proportion of patients with complete response (CR) and partial response (PR). Follow-up assessments after cycle 16 to be done every 12 weeks for up to 24 months. Restaging imaging computed tomography (CT) scans to be repeated 12 and 24 months from the beginning of the follow-up period. Objective disease response (CR and PR) defined according to the modified 2007 International Working Group (IWG) response criteria for non-Hodgkin lymphomas (NHL). CR = Disappearance of all evidence of disease; PR = Regression of measurable disease and no new sites. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Duration of Response (DOR) | Up to 24 months post treatment | DOR: The number of days between the first tumor response assessment of objective response (complete response and partial response) to the time of the first tumor response assessment of progressive disease (PD) or death if due to disease progression (date of first PD assessment or death due to disease progression-date of first objective response assessment +1). |
| Time to Disease Progression (TTP) | Up to 24 months post treatment | Investigators intended to report median time and its 95% confidence interval estimate using the Kaplan-Meier method, for 20 participants. Progressive disease (PD) defined according to the modified 2007 International Working Group (IWG) response criteria for non-Hodgkin lymphomas (NHL). |
| Time to Response (TTR) | Up to 24 months post treatment | Investigators intended to report median time and its 95% confidence interval estimate using the Kaplan-Meier method, for 20 participants. TTR: The time from the start of treatment to the first time when the measurement criteria for CR or PR are met. Participants who did not have a confirmed response to be censored at the date of the last tumor assessment. |
| Overall Survival (OS) | 24 months post treatment or until study closure | Investigators intended to report median time and its 95% confidence interval estimate using the Kaplan-Meier method, for 20 participants. Radiological assessments to be discontinued at the time of tumor progression or initiation of new anticancer therapy, after which survival to be evaluated every 3 months until 2 years from the start of study treatment or until study closure. |
| Number of Participants With Study Related Serious Adverse Events (SAEs) | Up to 24 months post treatment | Serious adverse events (SAEs) to be summarized by worst NCI NCI Common Terminology Criteria for Adverse Events (CTCAE) grade. |
| Progression Free Survival (PFS) | 24 months post treatment | Investigators intended to report median time and its 95% confidence interval estimate using the Kaplan-Meier method, for 20 participants. Stable disease (SD) defined according to the modified 2007 International Working Group (IWG) response criteria for non-Hodgkin lymphomas (NHL). |
Countries
United States
Participant flow
Recruitment details
One participant was enrolled in June 2015 at Moffitt Cancer Center. Soon after the accrual of this one participant, the sponsor terminated their support of the project.
Participants by arm
| Arm | Count |
|---|---|
| Brentuximab Vedotin Treatment Brentuximab vedotin will be given intravenously with a dose of 1.8 mg/kg every 21 days, over 30 minutes for 16 cycles in the clinic. | 1 |
| Total | 1 |
Baseline characteristics
| Characteristic | Brentuximab Vedotin Treatment |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 1 Participants |
| Age, Categorical Between 18 and 65 years | 0 Participants |
| Age, Continuous | 68 68 |
| Gender Female | 1 Participants |
| Gender Male | 0 Participants |
| Region of Enrollment United States | 1 participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 1 / 1 |
| serious Total, serious adverse events | 0 / 1 |
Outcome results
Primary
Overall Response Rate (ORR)
ORR: The proportion of patients with complete response (CR) and partial response (PR). Follow-up assessments after cycle 16 to be done every 12 weeks for up to 24 months. Restaging imaging computed tomography (CT) scans to be repeated 12 and 24 months from the beginning of the follow-up period. Objective disease response (CR and PR) defined according to the modified 2007 International Working Group (IWG) response criteria for non-Hodgkin lymphomas (NHL). CR = Disappearance of all evidence of disease; PR = Regression of measurable disease and no new sites.
Time frame: Up to 24 months post treatment
Population: All participants.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Brentuximab Vedotin Treatment | Overall Response Rate (ORR) | Participants with Complete Response | 0 Participants |
| Brentuximab Vedotin Treatment | Overall Response Rate (ORR) | Participants with Partial Response | 0 Participants |
| Brentuximab Vedotin Treatment | Overall Response Rate (ORR) | Participants with Stable Disease | 1 Participants |
Secondary
Duration of Response (DOR)
DOR: The number of days between the first tumor response assessment of objective response (complete response and partial response) to the time of the first tumor response assessment of progressive disease (PD) or death if due to disease progression (date of first PD assessment or death due to disease progression-date of first objective response assessment +1).
Time frame: Up to 24 months post treatment
Population: Participants with Complete Response or Partial Response.
Secondary
Number of Participants With Study Related Serious Adverse Events (SAEs)
Serious adverse events (SAEs) to be summarized by worst NCI NCI Common Terminology Criteria for Adverse Events (CTCAE) grade.
Time frame: Up to 24 months post treatment
Population: All participants.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Brentuximab Vedotin Treatment | Number of Participants With Study Related Serious Adverse Events (SAEs) | 0 Participants |
Secondary
Overall Survival (OS)
Investigators intended to report median time and its 95% confidence interval estimate using the Kaplan-Meier method, for 20 participants. Radiological assessments to be discontinued at the time of tumor progression or initiation of new anticancer therapy, after which survival to be evaluated every 3 months until 2 years from the start of study treatment or until study closure.
Time frame: 24 months post treatment or until study closure
Population: Participants evaluable at 24 months post treatment or at study closure.
Secondary
Progression Free Survival (PFS)
Investigators intended to report median time and its 95% confidence interval estimate using the Kaplan-Meier method, for 20 participants. Stable disease (SD) defined according to the modified 2007 International Working Group (IWG) response criteria for non-Hodgkin lymphomas (NHL).
Time frame: 24 months post treatment
Population: Participants evaluable at 24 months post treatment.
Secondary
Time to Disease Progression (TTP)
Investigators intended to report median time and its 95% confidence interval estimate using the Kaplan-Meier method, for 20 participants. Progressive disease (PD) defined according to the modified 2007 International Working Group (IWG) response criteria for non-Hodgkin lymphomas (NHL).
Time frame: Up to 24 months post treatment
Population: All participants.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Brentuximab Vedotin Treatment | Time to Disease Progression (TTP) | 10 months |
Secondary
Time to Response (TTR)
Investigators intended to report median time and its 95% confidence interval estimate using the Kaplan-Meier method, for 20 participants. TTR: The time from the start of treatment to the first time when the measurement criteria for CR or PR are met. Participants who did not have a confirmed response to be censored at the date of the last tumor assessment.
Time frame: Up to 24 months post treatment
Population: Participants with Complete Response or Partial Response.